 | • レポートコード：QFJ1-4452 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、126ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、黄斑変性症治療薬パイプラインの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（遺伝子治療、小分子、幹細胞治療、遺伝子治療）、用途別市場規模（病院、研究所、商業、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・黄斑変性症治療薬パイプラインの市場動向 ・企業の競争状況、市場シェア ・黄斑変性症治療薬パイプラインの種類別市場規模と予測2016-2027（遺伝子治療、小分子、幹細胞治療、遺伝子治療） ・黄斑変性症治療薬パイプラインの用途別市場規模と予測2016-2027（病院、研究所、商業、その他） ・黄斑変性症治療薬パイプラインの北米市場規模2016-2027（アメリカ、カナダ） ・黄斑変性症治療薬パイプラインの欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・黄斑変性症治療薬パイプラインのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・黄斑変性症治療薬パイプラインの中南米市場規模2016-2027（メキシコ、ブラジル） ・黄斑変性症治療薬パイプラインの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Amgen、Roche、Adverum Biotechnologies、AsclepiX Therapeutics、Bioeq AG、Sinocelltech、RemeGen、Grifols, S.A.、Kyowa Kirin、EyePoint Pharmaceutical、IVERIC Bio、Kodiak Sciences、Ribomic、Lineage Cell Therapeutics、Graybug Vision、CHABiotech、Shanghai Henlius Biotech、Bio-Thera Solutions、Alteogen、Outlook Therapeutics） ・結論 |
Market Analysis and Insights: Global Macular Degeneration Drug Pipeline Market
The global Macular Degeneration Drug Pipeline market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Macular Degeneration Drug Pipeline market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Macular Degeneration Drug Pipeline market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Macular Degeneration Drug Pipeline market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Macular Degeneration Drug Pipeline market.
Global Macular Degeneration Drug Pipeline Scope and Market Size
Macular Degeneration Drug Pipeline market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Macular Degeneration Drug Pipeline market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Gene therapy
Small molecules
Stem cell therapy
Gene therapies
Segment by Application
Hospital
Research Institute
Commercial
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Amgen
Roche
Adverum Biotechnologies
AsclepiX Therapeutics
Bioeq AG
Sinocelltech
RemeGen
Grifols, S.A.
Kyowa Kirin
EyePoint Pharmaceutical
IVERIC Bio
Kodiak Sciences
Ribomic
Lineage Cell Therapeutics
Graybug Vision
CHABiotech
Shanghai Henlius Biotech
Bio-Thera Solutions
Alteogen
Outlook Therapeutics
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Macular Degeneration Drug Pipeline Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Gene therapy
1.2.3 Small molecules
1.2.4 Stem cell therapy
1.2.5 Gene therapies
1.3 Market by Application
1.3.1 Global Macular Degeneration Drug Pipeline Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Research Institute
1.3.4 Commercial
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Macular Degeneration Drug Pipeline Market Perspective (2016-2027)
2.2 Macular Degeneration Drug Pipeline Growth Trends by Regions
2.2.1 Macular Degeneration Drug Pipeline Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Macular Degeneration Drug Pipeline Historic Market Share by Regions (2016-2021)
2.2.3 Macular Degeneration Drug Pipeline Forecasted Market Size by Regions (2022-2027)
2.3 Macular Degeneration Drug Pipeline Industry Dynamic
2.3.1 Macular Degeneration Drug Pipeline Market Trends
2.3.2 Macular Degeneration Drug Pipeline Market Drivers
2.3.3 Macular Degeneration Drug Pipeline Market Challenges
2.3.4 Macular Degeneration Drug Pipeline Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue
3.1.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue (2016-2021)
3.1.2 Global Macular Degeneration Drug Pipeline Revenue Market Share by Players (2016-2021)
3.2 Global Macular Degeneration Drug Pipeline Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Macular Degeneration Drug Pipeline Revenue
3.4 Global Macular Degeneration Drug Pipeline Market Concentration Ratio
3.4.1 Global Macular Degeneration Drug Pipeline Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Macular Degeneration Drug Pipeline Revenue in 2020
3.5 Macular Degeneration Drug Pipeline Key Players Head office and Area Served
3.6 Key Players Macular Degeneration Drug Pipeline Product Solution and Service
3.7 Date of Enter into Macular Degeneration Drug Pipeline Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Macular Degeneration Drug Pipeline Breakdown Data by Type
4.1 Global Macular Degeneration Drug Pipeline Historic Market Size by Type (2016-2021)
4.2 Global Macular Degeneration Drug Pipeline Forecasted Market Size by Type (2022-2027)
5 Macular Degeneration Drug Pipeline Breakdown Data by Application
5.1 Global Macular Degeneration Drug Pipeline Historic Market Size by Application (2016-2021)
5.2 Global Macular Degeneration Drug Pipeline Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Macular Degeneration Drug Pipeline Market Size (2016-2027)
6.2 North America Macular Degeneration Drug Pipeline Market Size by Type
6.2.1 North America Macular Degeneration Drug Pipeline Market Size by Type (2016-2021)
6.2.2 North America Macular Degeneration Drug Pipeline Market Size by Type (2022-2027)
6.2.3 North America Macular Degeneration Drug Pipeline Market Size by Type (2016-2027)
6.3 North America Macular Degeneration Drug Pipeline Market Size by Application
6.3.1 North America Macular Degeneration Drug Pipeline Market Size by Application (2016-2021)
6.3.2 North America Macular Degeneration Drug Pipeline Market Size by Application (2022-2027)
6.3.3 North America Macular Degeneration Drug Pipeline Market Size by Application (2016-2027)
6.4 North America Macular Degeneration Drug Pipeline Market Size by Country
6.4.1 North America Macular Degeneration Drug Pipeline Market Size by Country (2016-2021)
6.4.2 North America Macular Degeneration Drug Pipeline Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Macular Degeneration Drug Pipeline Market Size (2016-2027)
7.2 Europe Macular Degeneration Drug Pipeline Market Size by Type
7.2.1 Europe Macular Degeneration Drug Pipeline Market Size by Type (2016-2021)
7.2.2 Europe Macular Degeneration Drug Pipeline Market Size by Type (2022-2027)
7.2.3 Europe Macular Degeneration Drug Pipeline Market Size by Type (2016-2027)
7.3 Europe Macular Degeneration Drug Pipeline Market Size by Application
7.3.1 Europe Macular Degeneration Drug Pipeline Market Size by Application (2016-2021)
7.3.2 Europe Macular Degeneration Drug Pipeline Market Size by Application (2022-2027)
7.3.3 Europe Macular Degeneration Drug Pipeline Market Size by Application (2016-2027)
7.4 Europe Macular Degeneration Drug Pipeline Market Size by Country
7.4.1 Europe Macular Degeneration Drug Pipeline Market Size by Country (2016-2021)
7.4.2 Europe Macular Degeneration Drug Pipeline Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size (2016-2027)
8.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type
8.2.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type (2016-2027)
8.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application
8.3.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application (2016-2027)
8.4 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region
8.4.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Macular Degeneration Drug Pipeline Market Size (2016-2027)
9.2 Latin America Macular Degeneration Drug Pipeline Market Size by Type
9.2.1 Latin America Macular Degeneration Drug Pipeline Market Size by Type (2016-2021)
9.2.2 Latin America Macular Degeneration Drug Pipeline Market Size by Type (2022-2027)
9.2.3 Latin America Macular Degeneration Drug Pipeline Market Size by Type (2016-2027)
9.3 Latin America Macular Degeneration Drug Pipeline Market Size by Application
9.3.1 Latin America Macular Degeneration Drug Pipeline Market Size by Application (2016-2021)
9.3.2 Latin America Macular Degeneration Drug Pipeline Market Size by Application (2022-2027)
9.3.3 Latin America Macular Degeneration Drug Pipeline Market Size by Application (2016-2027)
9.4 Latin America Macular Degeneration Drug Pipeline Market Size by Country
9.4.1 Latin America Macular Degeneration Drug Pipeline Market Size by Country (2016-2021)
9.4.2 Latin America Macular Degeneration Drug Pipeline Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size (2016-2027)
10.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type
10.2.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type (2016-2027)
10.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application
10.3.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application (2016-2027)
10.4 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country
10.4.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen Macular Degeneration Drug Pipeline Introduction
11.1.4 Amgen Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.1.5 Amgen Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Macular Degeneration Drug Pipeline Introduction
11.2.4 Roche Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.2.5 Roche Recent Development
11.3 Adverum Biotechnologies
11.3.1 Adverum Biotechnologies Company Details
11.3.2 Adverum Biotechnologies Business Overview
11.3.3 Adverum Biotechnologies Macular Degeneration Drug Pipeline Introduction
11.3.4 Adverum Biotechnologies Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.3.5 Adverum Biotechnologies Recent Development
11.4 AsclepiX Therapeutics
11.4.1 AsclepiX Therapeutics Company Details
11.4.2 AsclepiX Therapeutics Business Overview
11.4.3 AsclepiX Therapeutics Macular Degeneration Drug Pipeline Introduction
11.4.4 AsclepiX Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.4.5 AsclepiX Therapeutics Recent Development
11.5 Bioeq AG
11.5.1 Bioeq AG Company Details
11.5.2 Bioeq AG Business Overview
11.5.3 Bioeq AG Macular Degeneration Drug Pipeline Introduction
11.5.4 Bioeq AG Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.5.5 Bioeq AG Recent Development
11.6 Sinocelltech
11.6.1 Sinocelltech Company Details
11.6.2 Sinocelltech Business Overview
11.6.3 Sinocelltech Macular Degeneration Drug Pipeline Introduction
11.6.4 Sinocelltech Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.6.5 Sinocelltech Recent Development
11.7 RemeGen
11.7.1 RemeGen Company Details
11.7.2 RemeGen Business Overview
11.7.3 RemeGen Macular Degeneration Drug Pipeline Introduction
11.7.4 RemeGen Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.7.5 RemeGen Recent Development
11.8 Grifols, S.A.
11.8.1 Grifols, S.A. Company Details
11.8.2 Grifols, S.A. Business Overview
11.8.3 Grifols, S.A. Macular Degeneration Drug Pipeline Introduction
11.8.4 Grifols, S.A. Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.8.5 Grifols, S.A. Recent Development
11.9 Kyowa Kirin
11.9.1 Kyowa Kirin Company Details
11.9.2 Kyowa Kirin Business Overview
11.9.3 Kyowa Kirin Macular Degeneration Drug Pipeline Introduction
11.9.4 Kyowa Kirin Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.9.5 Kyowa Kirin Recent Development
11.10 EyePoint Pharmaceutical
11.10.1 EyePoint Pharmaceutical Company Details
11.10.2 EyePoint Pharmaceutical Business Overview
11.10.3 EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Introduction
11.10.4 EyePoint Pharmaceutical Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.10.5 EyePoint Pharmaceutical Recent Development
11.11 IVERIC Bio
11.11.1 IVERIC Bio Company Details
11.11.2 IVERIC Bio Business Overview
11.11.3 IVERIC Bio Macular Degeneration Drug Pipeline Introduction
11.11.4 IVERIC Bio Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.11.5 IVERIC Bio Recent Development
11.12 Kodiak Sciences
11.12.1 Kodiak Sciences Company Details
11.12.2 Kodiak Sciences Business Overview
11.12.3 Kodiak Sciences Macular Degeneration Drug Pipeline Introduction
11.12.4 Kodiak Sciences Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.12.5 Kodiak Sciences Recent Development
11.13 Ribomic
11.13.1 Ribomic Company Details
11.13.2 Ribomic Business Overview
11.13.3 Ribomic Macular Degeneration Drug Pipeline Introduction
11.13.4 Ribomic Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.13.5 Ribomic Recent Development
11.14 Lineage Cell Therapeutics
11.14.1 Lineage Cell Therapeutics Company Details
11.14.2 Lineage Cell Therapeutics Business Overview
11.14.3 Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Introduction
11.14.4 Lineage Cell Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.14.5 Lineage Cell Therapeutics Recent Development
11.15 Graybug Vision
11.15.1 Graybug Vision Company Details
11.15.2 Graybug Vision Business Overview
11.15.3 Graybug Vision Macular Degeneration Drug Pipeline Introduction
11.15.4 Graybug Vision Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.15.5 Graybug Vision Recent Development
11.16 CHABiotech
11.16.1 CHABiotech Company Details
11.16.2 CHABiotech Business Overview
11.16.3 CHABiotech Macular Degeneration Drug Pipeline Introduction
11.16.4 CHABiotech Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.16.5 CHABiotech Recent Development
11.17 Shanghai Henlius Biotech
11.17.1 Shanghai Henlius Biotech Company Details
11.17.2 Shanghai Henlius Biotech Business Overview
11.17.3 Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Introduction
11.17.4 Shanghai Henlius Biotech Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.17.5 Shanghai Henlius Biotech Recent Development
11.18 Bio-Thera Solutions
11.18.1 Bio-Thera Solutions Company Details
11.18.2 Bio-Thera Solutions Business Overview
11.18.3 Bio-Thera Solutions Macular Degeneration Drug Pipeline Introduction
11.18.4 Bio-Thera Solutions Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.18.5 Bio-Thera Solutions Recent Development
11.18 Alteogen
.1 Alteogen Company Details
.2 Alteogen Business Overview
.3 Alteogen Macular Degeneration Drug Pipeline Introduction
.4 Alteogen Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
.5 Alteogen Recent Development
11.20 Outlook Therapeutics
11.20.1 Outlook Therapeutics Company Details
11.20.2 Outlook Therapeutics Business Overview
11.20.3 Outlook Therapeutics Macular Degeneration Drug Pipeline Introduction
11.20.4 Outlook Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
11.20.5 Outlook Therapeutics Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Macular Degeneration Drug Pipeline Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Gene therapy
Table 3. Key Players of Small molecules
Table 4. Key Players of Stem cell therapy
Table 5. Key Players of Gene therapies
Table 6. Global Macular Degeneration Drug Pipeline Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Macular Degeneration Drug Pipeline Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Macular Degeneration Drug Pipeline Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Macular Degeneration Drug Pipeline Market Share by Regions (2016-2021)
Table 10. Global Macular Degeneration Drug Pipeline Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Macular Degeneration Drug Pipeline Market Share by Regions (2022-2027)
Table 12. Macular Degeneration Drug Pipeline Market Trends
Table 13. Macular Degeneration Drug Pipeline Market Drivers
Table 14. Macular Degeneration Drug Pipeline Market Challenges
Table 15. Macular Degeneration Drug Pipeline Market Restraints
Table 16. Global Macular Degeneration Drug Pipeline Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Macular Degeneration Drug Pipeline Market Share by Players (2016-2021)
Table 18. Global Top Macular Degeneration Drug Pipeline Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Macular Degeneration Drug Pipeline as of 2020)
Table 19. Ranking of Global Top Macular Degeneration Drug Pipeline Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Macular Degeneration Drug Pipeline Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Macular Degeneration Drug Pipeline Product Solution and Service
Table 23. Date of Enter into Macular Degeneration Drug Pipeline Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Macular Degeneration Drug Pipeline Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Macular Degeneration Drug Pipeline Revenue Market Share by Type (2016-2021)
Table 27. Global Macular Degeneration Drug Pipeline Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Macular Degeneration Drug Pipeline Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Macular Degeneration Drug Pipeline Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Macular Degeneration Drug Pipeline Revenue Market Share by Application (2016-2021)
Table 31. Global Macular Degeneration Drug Pipeline Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Macular Degeneration Drug Pipeline Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Macular Degeneration Drug Pipeline Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Macular Degeneration Drug Pipeline Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Macular Degeneration Drug Pipeline Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Macular Degeneration Drug Pipeline Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Macular Degeneration Drug Pipeline Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Macular Degeneration Drug Pipeline Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Macular Degeneration Drug Pipeline Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Macular Degeneration Drug Pipeline Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Macular Degeneration Drug Pipeline Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Macular Degeneration Drug Pipeline Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Macular Degeneration Drug Pipeline Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Macular Degeneration Drug Pipeline Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Macular Degeneration Drug Pipeline Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Macular Degeneration Drug Pipeline Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Macular Degeneration Drug Pipeline Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Macular Degeneration Drug Pipeline Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Macular Degeneration Drug Pipeline Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Macular Degeneration Drug Pipeline Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2022-2027) & (US$ Million)
Table 63. Amgen Company Details
Table 64. Amgen Business Overview
Table 65. Amgen Macular Degeneration Drug Pipeline Product
Table 66. Amgen Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 67. Amgen Recent Development
Table 68. Roche Company Details
Table 69. Roche Business Overview
Table 70. Roche Macular Degeneration Drug Pipeline Product
Table 71. Roche Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 72. Roche Recent Development
Table 73. Adverum Biotechnologies Company Details
Table 74. Adverum Biotechnologies Business Overview
Table 75. Adverum Biotechnologies Macular Degeneration Drug Pipeline Product
Table 76. Adverum Biotechnologies Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 77. Adverum Biotechnologies Recent Development
Table 78. AsclepiX Therapeutics Company Details
Table 79. AsclepiX Therapeutics Business Overview
Table 80. AsclepiX Therapeutics Macular Degeneration Drug Pipeline Product
Table 81. AsclepiX Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 82. AsclepiX Therapeutics Recent Development
Table 83. Bioeq AG Company Details
Table 84. Bioeq AG Business Overview
Table 85. Bioeq AG Macular Degeneration Drug Pipeline Product
Table 86. Bioeq AG Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 87. Bioeq AG Recent Development
Table 88. Sinocelltech Company Details
Table 89. Sinocelltech Business Overview
Table 90. Sinocelltech Macular Degeneration Drug Pipeline Product
Table 91. Sinocelltech Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 92. Sinocelltech Recent Development
Table 93. RemeGen Company Details
Table 94. RemeGen Business Overview
Table 95. RemeGen Macular Degeneration Drug Pipeline Product
Table 96. RemeGen Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 97. RemeGen Recent Development
Table 98. Grifols, S.A. Company Details
Table 99. Grifols, S.A. Business Overview
Table 100. Grifols, S.A. Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 101. Grifols, S.A. Recent Development
Table 102. Kyowa Kirin Company Details
Table 103. Kyowa Kirin Business Overview
Table 104. Kyowa Kirin Macular Degeneration Drug Pipeline Product
Table 105. Kyowa Kirin Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 106. Kyowa Kirin Recent Development
Table 107. EyePoint Pharmaceutical Company Details
Table 108. EyePoint Pharmaceutical Business Overview
Table 109. EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Product
Table 110. EyePoint Pharmaceutical Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 111. EyePoint Pharmaceutical Recent Development
Table 112. IVERIC Bio Company Details
Table 113. IVERIC Bio Business Overview
Table 114. IVERIC Bio Macular Degeneration Drug Pipeline Product
Table 115. IVERIC Bio Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 116. IVERIC Bio Recent Development
Table 117. Kodiak Sciences Company Details
Table 118. Kodiak Sciences Business Overview
Table 119. Kodiak Sciences Macular Degeneration Drug Pipeline Product
Table 120. Kodiak Sciences Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 121. Kodiak Sciences Recent Development
Table 122. Ribomic Company Details
Table 123. Ribomic Business Overview
Table 124. Ribomic Macular Degeneration Drug Pipeline Product
Table 125. Ribomic Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 126. Ribomic Recent Development
Table 127. Lineage Cell Therapeutics Company Details
Table 128. Lineage Cell Therapeutics Business Overview
Table 129. Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Product
Table 130. Lineage Cell Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 131. Lineage Cell Therapeutics Recent Development
Table 132. Graybug Vision Company Details
Table 133. Graybug Vision Business Overview
Table 134. Graybug Vision Macular Degeneration Drug Pipeline Product
Table 135. Graybug Vision Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 136. Graybug Vision Recent Development
Table 137. CHABiotech Company Details
Table 138. CHABiotech Business Overview
Table 139. CHABiotech Macular Degeneration Drug Pipeline Product
Table 140. CHABiotech Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 141. CHABiotech Recent Development
Table 142. Shanghai Henlius Biotech Company Details
Table 143. Shanghai Henlius Biotech Business Overview
Table 144. Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Product
Table 145. Shanghai Henlius Biotech Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 146. Shanghai Henlius Biotech Recent Development
Table 147. Bio-Thera Solutions Company Details
Table 148. Bio-Thera Solutions Business Overview
Table 149. Bio-Thera Solutions Macular Degeneration Drug Pipeline Product
Table 150. Bio-Thera Solutions Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 151. Bio-Thera Solutions Recent Development
Table 152. Alteogen Company Details
Table 153. Alteogen Business Overview
Table 154. Alteogen Macular Degeneration Drug Pipeline Product
Table 155. Alteogen Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 156. Alteogen Recent Development
Table 157. Outlook Therapeutics Company Details
Table 158. Outlook Therapeutics Business Overview
Table 159. Outlook Therapeutics Macular Degeneration Drug Pipeline Product
Table 160. Outlook Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2016-2021) & (US$ Million)
Table 161. Outlook Therapeutics Recent Development
Table 162. Research Programs/Design for This Report
Table 163. Key Data Information from Secondary Sources
Table 164. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Macular Degeneration Drug Pipeline Market Share by Type: 2020 VS 2027
Figure 2. Gene therapy Features
Figure 3. Small molecules Features
Figure 4. Stem cell therapy Features
Figure 5. Gene therapies Features
Figure 6. Global Macular Degeneration Drug Pipeline Market Share by Application: 2020 VS 2027
Figure 7. Hospital Case Studies
Figure 8. Research Institute Case Studies
Figure 9. Commercial Case Studies
Figure 10. Other Case Studies
Figure 11. Macular Degeneration Drug Pipeline Report Years Considered
Figure 12. Global Macular Degeneration Drug Pipeline Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Macular Degeneration Drug Pipeline Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Macular Degeneration Drug Pipeline Market Share by Regions: 2020 VS 2027
Figure 15. Global Macular Degeneration Drug Pipeline Market Share by Regions (2022-2027)
Figure 16. Global Macular Degeneration Drug Pipeline Market Share by Players in 2020
Figure 17. Global Top Macular Degeneration Drug Pipeline Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Macular Degeneration Drug Pipeline as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Macular Degeneration Drug Pipeline Revenue in 2020
Figure 19. Global Macular Degeneration Drug Pipeline Revenue Market Share by Type (2016-2021)
Figure 20. Global Macular Degeneration Drug Pipeline Revenue Market Share by Type (2022-2027)
Figure 21. North America Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Macular Degeneration Drug Pipeline Market Share by Type (2016-2027)
Figure 23. North America Macular Degeneration Drug Pipeline Market Share by Application (2016-2027)
Figure 24. North America Macular Degeneration Drug Pipeline Market Share by Country (2016-2027)
Figure 25. United States Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Macular Degeneration Drug Pipeline Market Share by Type (2016-2027)
Figure 29. Europe Macular Degeneration Drug Pipeline Market Share by Application (2016-2027)
Figure 30. Europe Macular Degeneration Drug Pipeline Market Share by Country (2016-2027)
Figure 31. Germany Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Macular Degeneration Drug Pipeline Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Macular Degeneration Drug Pipeline Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Macular Degeneration Drug Pipeline Market Share by Region (2016-2027)
Figure 41. China Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Macular Degeneration Drug Pipeline Market Share by Type (2016-2027)
Figure 49. Latin America Macular Degeneration Drug Pipeline Market Share by Application (2016-2027)
Figure 50. Latin America Macular Degeneration Drug Pipeline Market Share by Country (2016-2027)
Figure 51. Mexico Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Macular Degeneration Drug Pipeline Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Macular Degeneration Drug Pipeline Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Macular Degeneration Drug Pipeline Market Share by Country (2016-2027)
Figure 57. Turkey Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Macular Degeneration Drug Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Amgen Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 61. Roche Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 62. Adverum Biotechnologies Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 63. AsclepiX Therapeutics Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 64. Bioeq AG Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 65. Sinocelltech Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 66. RemeGen Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 67. Grifols, S.A. Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 68. Kyowa Kirin Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 69. EyePoint Pharmaceutical Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 70. IVERIC Bio Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 71. Kodiak Sciences Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 72. Ribomic Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 73. Lineage Cell Therapeutics Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 74. Graybug Vision Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 75. CHABiotech Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 76. Shanghai Henlius Biotech Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 77. Bio-Thera Solutions Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 78. Alteogen Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 79. Outlook Therapeutics Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2016-2021)
Figure 80. Bottom-up and Top-down Approaches for This Report
Figure 81. Data Triangulation
Figure 82. Key Executives Interviewed
加齢性黄斑変性症治療薬のグローバル市場2021 Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail. Age Related Macular Degeneration Drug is widely used…- 世界の加齢黄斑変性症（AMD）治療市場規模・現状・予測（2021年-2027年） Age-related macular degeneration is a bilateral ocular condition in which the central area of the retina, known as the macula, is affected. Age-related macular degeneration is a progressive condition, and it is common among the geriatric population. The growing geriatric population is contributing t…
- 世界の加齢黄斑変性症用治療市場規模・現状・予測（2021年-2027年） Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail. Market Analysis and Insights: Global Age Related Mac…
- 世界のウェット型黄斑変性症市場規模・現状・予測（2021年-2027年） Wet macular degeneration is a chronic eye disorder that induces vague vision or a blind spot in the patient's visual field. Market Analysis and Insights: Global Wet Macular Degeneration Market The global Wet Macular Degeneration market size is projected to reach US$ XX million by 2027, from US$ XX m…
- 加齢黄斑変性症(AMD)治療のグローバル市場：規模・現状・予測2019-2025 Age-related macular degeneration is a bilateral ocular condition in which the central area of the retina, known as the macula, is affected.Age-related macular degeneration is a progressive condition, and it is common among the geriatric population. The growing geriatric population is contributing to…